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In organized cervical screening programs, typically 25% of the invited women do not attend. The Copenhagen Self-sampling
Initiative (CSi) aimed to gain experiences on participation among screening nonattenders in the Capital Region of Denmark.
Here, we report on the effectiveness of different communication platforms used in the pilot with suggestions for strategies
prior to a full-implementation. Moreover, an innovative approach using self-sampling brushes with unique radio frequency
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identification chips allowed for unprecedented levels patient identification safety. Nonattenders from the capital region of
Denmark were identified via the organized national invitation module. Screening history was obtained via the nationwide
pathology registry. Twenty-four thousand women were invited, and as an alternative to the regular communication platforms
(letter and phone), women could request a home test via a mobile-friendly webpage. Instruction material and video-animation
in several languages were made available online. Chi-square test was used to test differences. Out of all invited, 31.7%
requested a home test, and 20% returned it to the laboratory. In addition, 10% were screened at the physician after receiving
the invitation. Stratified by screening history, long-term unscreened women were less likely to participate than intermittently
screened women (28% vs. 16%, p< 0.001). Of all contacts received, 64% (63–65) came via letter, and 31% (95CI: 30–32%)
via webpage/mobile-app. Self-sampling was well-accepted among nonattenders. Adopting modern technology-based platforms
into the current organized screening program would serve as a convenient communication method between health authority
and citizens, allowing easy access for the citizen and reducing the work load in administrating self-sampling approaches.
In Denmark, screening coverage is 75%,1 but 45% of all cer-
vical cancer cases are diagnosed among the 25% nonattend-
ing women, who have not been screened as recommended
(nonattenders).2 Therefore, an increased screening coverage
through recruitment of nonattenders might decrease the inci-
dence of cervical cancer. Cytology-based cervical screening
samples are at present taken by healthcare professionals
during a gynecological examination. In Denmark and many
European countries, cervical screening is free of charge.
The gynecological examinations associated with sampling,
however, pose a barrier for some women due to discomfort,
embarrassment, or lack of time.3
Human Papillomavirus (HPV)-based self-sampling is a
new potentially useful screening method for nonattenders,4,5
which, unlike cytology, allows women to take a screening
sample in the privacy of their home, at a convenient time
and without undergoing a gynecological examination. The
self-taken sample can be returned for analysis directly to the
laboratory using regular mail. In previous studies from
screening programs with high screening coverage rates, such
as the Netherlands and various Scandinavian countries, all
nonattenders were mailed self-sampling kits (“opt-out”
approach).6–9 This strategy, where 6–34% of nonattenders
returned their self-sampling kits for analysis,6,10 leads to
considerable waste of the distributed, but unused kits. An
alternative approach is to have nonattenders actively “opt in,”
that is, order the self-sampling kits if interested after receiv-
ing an invitation from the screening program. Only few stud-
ies11–16 have used the opt-in approach so far, with a reported
return rate of 9–39%. A general concern is that by requiring
additional effort from women to conﬁrm their willingness to
participate, this approach is vulnerable to low participation
rates.13,14
The aim of the Copenhagen Self-Sampling Initiative (CSi)
pilot implementation study was to offer opt-in self-sampling
to nonattenders. Similar to the current screening program,
self-sampling was a public health care offer and free of
charge, yet by invitation only. To increase convenience and
minimize the needed effort from the women, we combined
classical mail-based correspondence with a custom-developed
web platform that could also be used on mobile devices to
order a self-sampling kit. In contrast to the current screening
program, selected information and instruction material was
available in several languages so as to avoid potential lan-
guage barriers. The inclusion stage of the study is now com-
pleted and the women are currently undergoing clinical
follow-up. To gain insight into the association between age,
and screening history to the acceptance of self-sampling as
an alternative to the current organized screening offer, we
described the percentage of women responding to an invita-
tion for a self-testing kit, and the percentage of kits returned,
stratiﬁed by age and previous screening history.
Material and Methods
Study population
Danish women are invited for liquid-based cytology screen-
ing every three years at 23–49 and every 5 years at 50–59
years of age. Since 2012, women aged 60–65 years have been
recommended to undergo HPV-based screening, after which
they leave the target group if HPV-negative.17 All screening
and the subsequent follow-up are free of charge. CSi is being
undertaken at Department of Pathology, Copenhagen Univer-
sity Hospital Hvidovre. This Department is responsible for
and operates cervical cancer screening for the entire Capital
Region including the administration of invitations, covering
approximately one-third of the Danish population. Women
What’s new?
Our implementation study is the first to evaluate opt-in self-sampling for 24,000 screening nonattenders, which can be basis
for future routine implementation. Women could respond through a variety of communication channels (regular mail, phone
and custom-made web/mobile-app). Our study utilized self-sampling brushes with a novel RFID-chip for secure patient-
identification, eliminating inconveniences for the women to fill out forms on returning the brush and loss of brushes due to
missing identification.
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are invited for screening in 3 or 5 years, depending on their
age, after their last cervical sample registered in the Danish
Pathology Database (Patobank).18 The call-recall system is
run by the CGI Institute (www.cgi.dk) and is based on the
invitational module in the Patobank, combining the screening
information from the Patobank’s main pathology module
with the residency status information from the Danish popu-
lation register. Women are invited by a letter mailed to their
home address, and receive reminders 3 and 6 months later.
CSi eligibility was determined on April 6, 2014, and the list of
women was compiled by CGI at the Department’s request.
Women were eligible if they resided in, and received their last
routine screening invitation, from the Capital Region. They had,
despite reminders, no cervical sample taken in 12 months after
the last invitation. Thus, eligible women were unscreened for at
least 4 or 6 years, depending on their age. The youngest invited
women were 27 and the oldest 65 years of age. In Denmark, the
organized cervical screening program includes women 23–65
years of age. Even though the international consensus trends
towards initiation of HPV screening from age 30 or 35, we chose
in this ﬁrst Danish initiative to offer a uniform service deﬁned by
nonattendance interval rather than by age stratiﬁcation. Conse-
quently, the youngest women offered self-sampling was 27 years
of age. Women who actively opted out of the screening program,
and/or were registered in the Patobank as ineligible for screening
due to a hysterectomy (this registration is, though, highly incom-
plete) were not eligible. Using these criteria, 54,585 women were
eligible and were randomly grouped into batches of 1,000 (Fig.
1). Unique random numbers doubling as study identiﬁcation
numbers were selected with R version 3.1.1 (R Development
Core Team, Vienna, Austria). A gradual mailing of the batches
allowed the department to plan the capacities and the logistics
during this pilot period. For practical reasons, this list was linked
to personal identiﬁcation numbers, names and addresses on May
6, 2014. By then, 849 women became ineligible because they
moved out of the Department’s catchment area, underwent
screening, opted out of routine screening, or died. Their
addresses were unknown for study purposes.
The mailing of batches continued until, in line with ﬁnan-
cial considerations, the goal of approximately 5,000 returned
brushes was reached. As the CSi invitations could not be
entered into the Patobank’s invitational module, some
Figure 1. Flow chart of study design. (a) Women moved out of the region/country, got screened, opted out routine screening, or died before
the address linkage. (b) Our initial target was to receive approximately 5,000 self-sampling brushes. This was achieved after 24 batches of
invitations. (c) Webpage: access via desktop or mobile device. (d) 21 responses were received via a separate questionnaire study. Seven
women requested the self-sampling brush, and six of these returned their self-sampling test. (e) HPV-testing was performed within
10 working days as according to routine practice. Women, who were high-risk HPV-positive, were recommended to go to their doctor, and
have a cytology sample taken, whereas HPV-negative women were referred back to the routine screening programme.
C
an
ce
r
E
p
id
em
io
lo
g
y
2214 Human papillomavirus self-sampling for screening nonattenders
Int. J. Cancer: 140, 2212–2219 (2017) VC 2017 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of
UICC
women may have received new routinely scheduled screening
invitations while CSi was ongoing. New linkages to determine
which women were invited for routine screening were not
possible in this pilot.
Invitational procedure
When the study was launched, it received broad nationwide
media coverage on approximately 20 media outlets, including
radio, TV, online news and magazines and print newspapers.
Each invited woman received an invitation package which
included an information sheet, a reply form and a prestamped
envelope. The information sheet included information on the
association between HPV and cervical cancer, and stressed the
importance of regular screening. Women could opt into the
study by ordering a self-sampling kit by (1) returning the reply
form, (2) phone, (3) e-mail or (4) signing up on a dedicated
website (http://www.hpv-hjemmetest.dk). QR code was printed
on invitations for easy web-redirection access. Instruction man-
uals were also available online in languages covering the major
linguistic groups in the area (Danish, Arabic, French, Turkish
and English). An animated instruction video was available in
Danish and English. After receiving the opt-in response, the
self-sampling kits were sent out after approximately two to
three working days
In the invitation letter, women were informed that they
could participate in a separate Danish Cancer Society ques-
tionnaire study investigating the reasons for screening nonat-
tendance. Questionnaire participation did not affect eligibility
for participation in CSi. Twenty-one women responded to
their self-sampling invitation only via this substudy, of whom
six (<1%) returned the self-sampling brush.
Reminders were sent 8 weeks after the initial invitation. A self-
sampling kit with instruction material and a prestamped envelope
were sent to all women who agreed to participate. If not returned
for testing, women received a reminder letter 4 weeks later. Addi-
tional kits were sent to women who requested new ones.
The self-sampling kit
We used the Evalyn Brush (The Rovers, Oss, The Netherlands),
customized for CSi by embedment of a radio-frequency identiﬁ-
cation (RFID) chip. The chip ensured linkage between the
woman’s identity and the brush, securing correct patient identiﬁ-
cation without relying on paper documentation. After receiving
the brush in the laboratory, HPV-testing was performed within
10 working days according to routine practice. The HPV-results
were sent to participants by personal letter, in addition to the
general practitioner if the woman agreed to this. Women, who
were high-risk HPV-positive, were recommended to go to their
doctor to have a cytology sample taken.
Data sources
Women’s screening history was determined through a linkage
to the national Patobank from January 1, 2000 to December 1,
2015. All registered cytological samples were included in the
analysis. Patobank’s registration of cervical samples has been
nearly complete since the mid-2000s (unpublished data).
Statistical analysis
The analyses were based on the intention-to-treat principle.
Response was deﬁned among women who ordered the kit,
whereas participation was deﬁned among women who returned
the brush to the laboratory. Both were determined by
December 1, 2015, that is, within 7 months after the last batch
of invitations was sent out.
We deﬁned women with a cytology sample registered in
10 years before April 2014 as intermittently screened and
other women as long-term unscreened. These analyses were
limited to women aged 34 years, as they had been targeted
for screening for >10 years.
The time for the women to return the brush was calculated
as the number of days between the date the brush was sent out
and the date it was received back in the laboratory.
Pearson’s v2- test was used to compare the differences in
responses and participation by screening history and by
response method. Analyses were performed using Stata SE
13.1 (StataCorp, TX) and Microsoft Excel 2010 (Microsoft,
Redmond).
Ethical approval
CSi was a time-limited pilot implementation offer, mandated
by the Danish Health Authority and carried out by the
regional screening authority of the Capital Region. Ethical
approval was not required. Linkage of the study data with
the Patobank was approved by Danish Data Protection Agen-
cy (AHH-2015–084, I-Suite number: 04139).
Results
The ﬁrst batch was sent on May 23, 2014 and the last, 24th
batch on April 10, 2015. From these 24 pregrouped batches,
368 women became ineligible before address linkage and the
remaining 23,632 (99%) women were invited for self-
sampling (Fig. 1). The age distributions of the women with a
successful address linkage who were not invited (N5 30,104)
and those who were (N5 23,632) did not differ (p5 0.90).
Among the 23,632 invited women, 974 (4%; Table 1)
women had a new screening sample registered in the Pato-
bank before they received the invitation (but after the address
linkages were made), either because they responded to a new
routinely scheduled screening invitation or for some other
reason unrelated to CSi. In total, 7,484 (32%) women
responded by ordering the self-sampling brush, and 4,824
(20%) participated by returning it. These proportions slightly
increased with age, although, owing to large numbers, the
age-trends were statistically signiﬁcant (p< 0.001). In addi-
tion, 2,288 (10%) women had a physician-taken cytology
sample registered after their CSi invitation. This was higher
at younger (13–16%; <50 years) than at older (3–4%, 50
years) age (p< 0.001). Combined, 34% of all invited women
were screened by December 1, 2015, of which a majority
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through self-sampling. With 25% of women being unscreened
before this intervention,1 this represents approximately 8.5%
of the entire population targeted for screening, although it
should be noted that these women were screened with a
longer-than-recommended interval.
Among 8,749 intermittently screened women aged 34–65
years, 3,611 (41%) responded (Table 2). Among 10,074 long-
term unscreened women, this was 2,598 (26%; p< 0.001). Also
participation was higher among the intermittently screened
(N5 2,416, 28%) than the long-term unscreened (N5 1,599,
16%) women (p <0.001), as was screening by a physician sub-
sequent to a self-sampling invitation (1,106 (13%) versus 489
(5%), p< 0.001). In total, 46% of intermittently screened and
23% of long-term unscreened women underwent some form of
screening. If screening history was recategorized as never
screened versus ever screened, we would have seen similar pat-
terns for participation in each group: 14% for never-screened
women and 26% for ever screened women (data not tabulated).
Most women responded by regular mail (4,574, 61%) or
online (2,794, 37%; Table 3). Phone and email were seldom
used (136, 2%). Women responding online were slightly
younger than women using regular mail or phone.
Some invited women made several contacts with the labo-
ratory, predominantly via phone and e-mail, and to request
additional information before deciding on participation
(N5 308; 4% of all invited women; data not tabulated).
Overall, 50% of all brushes were returned for testing with-
in 15 days (Fig. 2). Almost no brushes were returned later
than in 150 days. Little variation in how quickly the brushes
were returned was observed by calendar month in which the
invitations were sent (Supporting Information Fig. 1), except
for a slight delay over the Christmas period.
Overall, 5,154 (22%) women responded after the ﬁrst invi-
tation, and an additional 2,330 (10%) after receiving a
reminder (Fig. 3). Similarly, brush reminder letters increased
the number of returned brushes (participation) from 3,258
(14%) to 4,824 (20%). The increases in the responses and
returned brushes after sending out reminders did not seem
to be age-dependent. The increase of the participation rate
after sending out reminders was, however, slightly higher for
Table 2. Responders and participants, by screening history
Screening history1 Invited (%)
Screened by self-sampling Screened by physician
Total
screened
(%)
Responders
(%)
Participants
(%)
Before
study invi-
tation2 (%)
After study
invitation2
(%)
Long-term unscreened 10,074 (100%) 2,598 (26%) 1,599 (16%) 187 (2%) 489 (5%) 2,275 (23%)
Intermittently screened 8,749 (100%) 3,611 (41%) 2,416 (28%) 500 (6%) 1,106 (13%) 4,022 (46%)
Total 18,823 (100%) 6,209 (33%) 4,015 (21%) 687 (4%) 1,595 (8%) 6,297 (33%)
p <0.001 <0.001 <0.001 <0.001 <0.001
Limited to women aged 34 years who had been eligible for screening for >10 years.
Responders5 women who ordered a brush. Participants5 women who returned their brush.
1Intermittently unscreened: cytology sample registered within the last 10 years (though not in the last screening round, see eligibility criteria). Long-term
unscreened: no cytology sample registered in the last 10 years.
2Women who did not also return a self-sampling kit.
Table 1. Responders and participants, by age group
Age group
(years) Invited (%)1
Screened by self-sampling Screened by physician
Total
screened (%)Responders (%) Participants (%)
Before study
invitation2
(%)
After study
invitation2 (%)
27–29 2,291 (100%) 575 (25%) 383 (17%) 127 (6%) 303 (13%) 813 (35%)
30–39 5,711 (100%) 1,750 (31%) 1,080 (19%) 386 (7%) 898 (16%) 2,364 (41%)
40–49 5,633 (100%) 1,890 (34%) 1,200 (21%) 319 (6%) 730 (13%) 2,249 (40%)
50–59 5,888 (100%) 1,991 (34%) 1,265 (21%) 100 (2%) 250 (4%) 1,615 (27%)
60–65 4,109 (100%) 1,278 (31%) 896 (22%) 42 (1%) 107 (3%) 1,045 (25%)
Total 23,632 (100%) 7,484 (32%) 4,824 (20%) 974 (4%) 2,288 (10%) 8,086 (34%)
p <0.001 <0.001 <0.001 <0.001 <0.001
Responders5 women who ordered a brush. Participants5 women who returned their brush.
1Among all eligible women with a successful address linkage (N553,736), the age distribution did not differ between women who were invited
(N523,632) and those who were not (N530,104) (p50.90).
2Women who did not also return a self-sampling kit.
C
an
ce
r
E
p
id
em
io
lo
g
y
2216 Human papillomavirus self-sampling for screening nonattenders
Int. J. Cancer: 140, 2212–2219 (2017) VC 2017 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of
UICC
intermittently screened women than long-term unscreened
(9% vs. 5%, respectively. Data not reported)
Discussion
Findings
In this ﬁrst Danish pilot implementation of opt-in HPV-
based self-sampling for screening nonattenders, women could
respond to the invitation through various communication
platforms with written information provided in several lan-
guages. In total, 20% of the nonattending women returned a
self-sampling kit for testing. This was, despite the opt-in
approach, substantially more than the proportion of women
who sought screening of their own accord. The intervention
was particularly acceptable for intermittently screened wom-
en, with the 28% participation in self-sampling contributing
to the 46% overall coverage during the study period. For
the long-term unscreened women, 16% participation was
observed. Only 11% of the invited women requested a brush
but did not return it, so loss of self-sampling kits was
limited.
The choice of the Evalyn brush may have inﬂuenced the
participation rates. We chose it based on the security consid-
eration of not distributing medical liquids to private homes.
Also, among Dutch women this brush was slightly more
acceptable than a lavage device.19 By our request, the manu-
facturer embedded a unique RFID chip into the each brush’s
handle. This allowed safe patient identiﬁcation without wom-
en needing to return sample identiﬁcation forms. Using the
RFID, all returned brushes could be correctly identiﬁed.
The returned self-sampling brushes were likely not the
only effect of the CSi invitations. We observed that 10% of
all invited women had a physician-taken cytology sample reg-
istered in the Patobank after receiving the CSi invitation. It is
unknown whether the CSi invitation was the main motiva-
tion for having a routine cytology sample taken, or whether
it acted in concert with other considerations. This effect,
however, differed markedly by age. Whereas about 15% of
younger women (27–49 years) underwent such sampling, this
was only 3–4% in older women (50–65 years). From this, it
could be speculated that older nonattenders speciﬁcally avoid
screening for not wanting to have the gynecology examina-
tion required for a physician-taken sample or because they
think that screening may no longer be needed. The question-
naire study by the Danish Cancer Society is underway to study
this.
Strength and limitations of the study
Women eligible for the study were randomly selected for CSi,
and were representative of all eligible nonattenders in the
Danish Capital Region. Their screening statuses were deter-
mined from national administrative registration, avoiding
subjective recall. As we could not use the updated informa-
tion on the women’s screening activities within the study
period, 4% of the invited women actually underwent
cytology-based screening prior to receiving a self-sampling
invitation. In a routine setup, the invitation module would be
updated on a daily basis allowing the invitations being tar-
geted at true nonattenders. The initial national media cover-
age of the CSi may have resulted in a somewhat higher
Figure 2. Response timea: Cumulative response time for all women
participating in self-sampling. Response time defined as number of
days between the self-sampling kit sent out to it being returned to
the laboratory.
Table 3. Response and participation, by response method
Response method
Median age of
responders
(years; IQR)
Responders
(%)1
Participants
(%)
Screened by
a physician2
(%)
Regular mail 49 (38–59) 4,547 (61%) 2,886 (60%) 216 (58%)
Phone call 51 (41–60) 99 (1%) 58 (1%) 11 (3%)
Webpage 45 (36–55) 2,794 (37%) 1,853 (38%) 140 (38%)
E-mail 41 (34–52) 37 (<1%) 21 (<1%) 3 (1%)
Total 48 (37–57) 7,484 (100%) 4,824 (100%) 370 (100%)
Responders5 women who ordered a brush. Participants5 women who returned their brush. Webpage5 access via desktop or mobile device.
Abbreviations: IQR: interquartile range. Note: Women may have made several contacts with the Department throughout the study period. The contact
in which the women ordered the self-sampling kit is counted here.
1Twenty-one women responded to us via a separate questionnaire study. Seven women requested a self-sampling brush and six returned it.
2Screened by physician without returning their self-sampling test.
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recruitment than can be expected in a steady state. Neverthe-
less, the effect was relatively small and time-limited, even if
statistically signiﬁcant (27% participation after the ﬁrst batch
versus 20% after the remaining 23 batches combined,
p< 0.001).
Comparison with other studies
The response to opt-in strategies tends to be lower compared
to opt-out strategies.20 Our choice for an opt-in strategy was
mainly based on considerations of cost of purchase and mail-
ing of self-sampling kits including the administration of
reminders. Two Swedish opt-in studies by Sanner et al.12 and
Stenvall et al.11 targeted women unscreened for 6 years. Their
screening history was determined from a cytology register,
suggesting that these women had been screened before. The
achieved participation rates, using the Qvintip device, were
39%12 and 31%.11 In the latter study, therefore, a similar par-
ticipation rate was achieved as in our intermittently screened
Group (28%). Both studies also observed the very long time
for self-sampling devices to be returned for testing. In anoth-
er Swedish opt-in study, Broberg et al.16 observed a 17% par-
ticipation rate among women who had not responded to at
least four screening invitations, which was similar to 16% in
our long-term unscreened group. An additional 9% chose to
undergo physician-taken sampling after the self-sampling
invitation. Intermittently screened women were more likely
to participate than long-term unscreened women. Giorgi-
Rossi et al. invited Italian women for opt-in self-sampling if
they had not responded to a routine invitation for 3–5
months.13,14 Here, 20% women participated when offered to
have the kit sent to home and 9–11% when they could pick
it up from a local pharmacy. In Denmark, this is the period
in which women still receive screening reminders; these
reminders almost double the participation rate.1 Women
selected for CSi were those who were harder to reach and
did not respond to the two reminders. Hence, the two Italian
studies showed a much lower participation rate than CSi.
Implications for operationalization of self-sampling
for nonattenders
In a routine screening program, the numbers of screening
samples are affected by the opening hours of general practi-
tioners and by public holidays. In our Department, this leads
to an up to 50% seasonal variation in the number of received
samples, with lowest numbers during the summer holidays.
We sent out CSi invitations throughout an entire calendar
year and observed no seasonal variation, with the exception
of a small delay over the Christmas period (Supporting Infor-
mation Fig. 1). This enables laboratories to plan operational
capacity more evenly over the course of a business year.
Figure 3. Response and participation before and after reminder letters sent out, by age groupa. (a) Left-hand side: Darker shade5 proportion of
responses out of all invited women after first invitation sent out. Lighter shade5 Proportion of responses out of all invited women after invitation
reminders sent out. Right-hand side: Darker shade5Proportion of returned self-sampling tests out of all invited women. Lighter shade5
Proportion of returned self-sampling tests out of all invited women after self-sample reminders sent out.
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Reminders led to a 9–11% increase in response, and to an
increase of 5–8% in returned brushes (Fig. 3). An “invitation-
reminder” strategy thus seems preferable if planning a full
routine roll-out, even though formal cost-effectiveness calcu-
lations to support this are still needed.
The option of multiple electronic platforms is a new feature.
Nowadays, 93% of Danes have a smartphone or cell phone, and
81% of these use it online.21 We developed a dedicated web-
page. This convenient and easy-to-use platform was used by
one-third of all responders and it was well accepted by all age
groups. Nevertheless, online communication methods were
used slightly more frequently by younger women—suggesting
that, with an inﬂux of ever younger birth cohorts into the
screening programme, online methods may, over time, become
increasingly important to reach nonattenders.
This study used approximately 1,600 kg of paper to
communicate with women (Supporting Information Table 1),
equaling to 51 sheets of paper and/or envelopes (plus the
accompanying postage) per returned brush. Adding to this
was the logistics of the mailing (invitations, reminders and
brushes) and administration of the responses and additional
questions from women, which were all handled by the
laboratory staff. These all need to be taken into account
when planning the capacities for a full roll-out.
Conclusions and policy implications
The combination of self-sampling with HPV testing has the
potential to improve screening participation among women
who participate infrequently or not at all. Our opt-in strategy
generated a reasonable response and brush return rate, and
the electronic communication platforms showed promising
uptake rates. However, long-term nonattenders remain a
challenging group to motivate for cervical screening.
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